Utilization of metabolic substrates in tumour and host tissues was determined in the presence or absence of two colonic tumours, the MAC16, which is capable of inducing cachexia in recipient animals, and the MAC13, which is of the same histological type, but without the effect on host body composition. Glucose utilization by different tissues was determined in vivo by the 2-deoxyglucose tracer technique. Glucose utilization by the MAC13 tumour was significantly higher than by the MAC16 tumour, and in animals bearing tumours of either type the tumour was the second major consumer of glucose after the brain. This extra demand for glucose was accompanied by a marked decrease in glucose utilization by the epididymal fat-pads, testes, colon, spleen, kidney and, in particular, the brain, in tumour-bearing animals irrespective of cachexia. The decrease in glucose consumption by the brain was at least as high as the metabolic demand by the tumour. This suggests that the tissues of tumour-bearing animals adapt to use substrates other than glucose and that alterations in glucose utilization are not responsible for the cachexia. Studies in vitro showed that brain metabolism in the tumourbearing state was maintained by an increased use of lactate and 3-hydroxybutyrate, accompanied by a 50 % increase in 3-oxoacid CoA-transferase. This was supported by studies in vivo which showed an increased metabolism of 3-hydroxybutyrate in tumour-bearing animals. Thus ketone bodies may be utilized as a metabolic fuel during the cancerbearing state, even though the nutritional conditions mimic the fed state.
INTRODUCTION
Biochemical changes in host tissues frequently occur in cancer patients, and depletion of host adipose tissue and muscle protein in cancer patients is an important parameter determining overall survival [1] . The reason for depletion of host tissues is not known, but is thought to arise from differences in metabolism in the tumour-bearing state. Thus some studies have shown that the daily energy expenditure and the resting metabolic rate are much higher in cancer patients than in controls, even though the energy intake was not significantly different between the two groups [2] . Although anorexia is common in cancer patients [3] , numerous studies have documented abnormalities of host metabolism, which together indicate that cancer cachexia is not the same as simple starvation [4] .
There are marked alterations in the carbohydrate metabolism of host tissues of both animals and patients with cancer, but how these alterations contribute to the cachexia remains speculative. Glucose metabolism in cancer cells is known to be elevated, owing to an altered membrane transport, which leads to an increased intracellular concentration [5] , with consequent increased lactate production by some tumours [6] . This in turn leads to an increased conversion of lactate into glucose in the liver via the Cori cycle, the activity of which is also found to be elevated in cancer patients with progressive weight loss, showing that lactate production rates are higher in these patients [7] . Decreased blood glucose values are often found in tumourbearing animals [8] , suggesting that the glucose availability is not sufficient to provide for both host and tumour. In addition, a decreased plasma insulin level is often found [9] , together with an elevated rate of gluconeogenesis from non-carbohydrate precursors [10] .
To try to determine the biochemical changes responsible for, or accompanying, cachexia, we have employed an experimental murine colon adenocarcinoma (MAC16), which produces extensive loss of host body weight, accompanied by decreases in both fat and lean body mass, but without a fall in food intake [11, 12] . This tumour is useful for the study of the mechanisms of cachexia, since in some cases growth of the tumour is not accompanied by weight loss [13] 
MATERIALS AND METHODS
Pure-strain NMRI mice were bred in our own colony and were fed on a rat and mouse breeding diet (Pilsbury, Birmingham, U.K.) and water ad libitum. Fragments of either the MAC 16 or MAC13 tumour were implanted into the flank of male NMRI mice (starting weight 24-26 g ) by means of a trocar, as described in [11, 12] . Animals 
Glucose utilization
The extent of glucose utilization by different tissues was investigated by using the 2-deoxyglucose tracer technique [14] . Briefly, animals were starved overnight and throughout the experiment, but given water ad libitum. The following morning they were injected intravenously with 30 ,Ci of 2-deoxy-D- [ [14] . Blood glucose concentration was determined on whole blood by using the o-toluidine reagent kit (Sigma Chemical Co., Poole, Dorset, U.K.). The concentration of radioactivity in the blood was determined on deproteinized neutralized samples with a dual 3H/14C analyser.
The accumulation of phosphorylated metabolites of 2DG was measured in selected tissues at the 60 min time point [14, 15] . Nuclear, Stevenage, Herts., U.K. The slices were incubated with 10 ml of fuel mixture containing 2.5 ,uCi of the labelled fuel in a flask containing a centre well and sealed with a Suba-seal.
Samples were gassed with 02/CO2 (19: 1) and incubated at 37°C for 1 h. At this time 0.3 ml of 5 M-HC104 was added to the medium to liberate the CO2, which was collected in 0.3 ml of 0.3 M-NaOH added to the centre well. After standing for 4 h to allow complete absorption, the contents of the centre well were added to 10 ml of Optiphase Hi-safe 3 scintillation fluid and the radioactivity was determined.
Determination of brain 3-oxoacid CoA-transferase
Brains were homogenized in 10 mM-Tris, pH 7.4, containing 0.25 M-sucrose and 1 mM-2-mercaptoethanol, and enzyme activity was determined in the supernatant fraction prepared by centrifugation at 30000 g for 20 min. The rate of acetoacetylCoA formation from 0.1 mM-succinyl-CoA was determined by the method of Williamson et al. [19] . Effect of tumour-bearing state on '4CO2 production from 3-hydroxybutyric acid (Amersham International)/kg and were placed in airtight metabolic cages with the entry air being pumped through CaCO3 (solid) to absorb any CO2. Metabolically produced 14CO2 was trapped in ethanolamine/ethoxyethanol (1:4, v/v), and samples were taken at specified time intervals and the radioactivity was determined directly in Optiphase scintillation fluid (FSA Laboratory Supplies, Loughborough, Leics., U.K.).
RESULTS
In order to understand the glucose dynamics of the MAC16 and MAC13 tumours in vivo, and the effects on host organs with the development of cachexia, glucose utilization was investigated by the 2DG tracer method [14] [15] [16] . Blood glucose levels in animals bearing the MAC13 tumour that had been starved overnight were similar to those in control non-tumour-bearing animals over a 60 min time period (Fig. I a) , whereas animals bearing the MAC16 tumour were hypoglycaemic as compared with either group, irrespective of the development of cachexia, although this was only significant at the 60 min time point.
However, the rate of disappearance of the label from [3H12DG (Fig. lb) organ. In all tumour-bearing animals the tumour was the second major consumer of glucose after the brain. This placed a high demand on the host, and was accompanied by a marked decrease in glucose utilization by the brain. In animals bearing the MAC 13 tumour, glucose consumption by the brain decreased by an amount equal to that used by the tumour, whereas, in animals bearing the MAC16 tumour, brain glucose consumption was decreased to a greater extent than glucose consumption by the tumour. In animals bearing the MAC16 tumour, glucose consumption was also significantly decreased in epididymal fatpads, testes, colon, spleen and kidney, but was not related to the presence of cachexia.
To investigate whether cachexia altered the retention of 2DGP in the various organs, a sequential double-labelling technique was applied, followed by an analysis of the two labels in 2DGP.
Since there was a marked initial decay of the precursor in the blood, the bulk of the pH]2DGP was synthesized in the tissues during the initial 35 min of the labelling period, and the 3H/14C ratio of tissue 2DGP was measured at the end of the experiment. Loss of 2DGP from the tissue would affect the 3H component of the ratio more than the 14C component, and therefore the 3H/14C ratio of 2DGP in the tissues was a measure of the retention of 2DGP, i.e. a low ratio indicated a high rate of loss. Since 10 times as much 3H radioactivity was administered as 14C, the 3H/14C ratio would be expected to be near 10 if both radioisotopes were incorporated into 2DGP at the 60 min time period and there was no loss of DGP. This was true for most control tissues, except for lung, colon, brain and kidney, in which the ratios were much lower ( Table 3 ). The lower ratio for brain has previously been reported [14] , and arises from an increased rate of loss of 2DGP from this tissue. When compared with control animals and MAC16-tumour-bearing animals without cachexia, the 3H/14C ratio for testes, lung and brain was significantly higher in cachectic animals bearing the MAC16 tumour (Table 3 ). This suggests a slow incorporation of 2DG into 2DGP, a low rate of utilization and, assuming that the energy requirements remain constant, that the tissues of cachectic animals adapt to use metabolic substrates other than glucose. The decrease in glucose utilization by organs in tumourbearing mice must be accompanied by an alteration in the preference of the substrate for energy production. To determine the preferred metabolic substrate, the utilization of glucose, lactate and 3-hydroxybutyrate was determined by using a substrate mixture with a high lactate concentration. The results for liver, brain and tumour are shown in Table 4 . At the concentration employed, lactate was the most important oxidative substrate for the liver in control and tumour-bearing animals, with the rate of utilization by liver slices from animals bearing the MAC13 tumour being significantly (P < 0.005) elevated over that of non tumour-bearing controls (Table 4 ). Both glucose and 3-hydroxybutyrate consumptions by the liver were low, and, although the former did not change in the tumour-bearing state, consumption of 3-hydroxybutyrate was significantly higher (P < 0.001) in animals bearing the MAC13 tumour.
Lactate was an important metabolic fuel for the tumour, and the rate of utilization was significantly greater (P < 0.001) in the MAC13 tumour. Although the glucose consumption rate was not significantly different for the two tumour types, the rate of utilization of 3-hydroxybutyrate was much higher in the MAC1 3 tumour.
For brain from non-tumour-bearing animals, glucose was the predominant metabolic fuel, followed by lactate, possibly owing to the supra-physiological lactate concentration, whereas in the brain of animals bearing the MAC16 tumour with cachexia, the rate of glucose utilization was decreased by two-thirds (P < 0.05) and was also significantly less than that in brains of animals bearing the MAC13 tumour (P < 0.005). This metabolic deficit produced by a decreased glucose consumption was accompanied by a marked increase in both lactate (P < 0.05) and 3-hydroxybutyrate (P < 0.01) utilization in the brains of animals bearing the MAC16 tumour, when compared with non-tumourbearing controls. This increased 3-hydroxybutyrate utilization in the brains of tumour-bearing animals is probably due to an increase in the level of 3-oxoacid CoA-transferase (EC 2.8.3.5), the rate-limiting enzyme in ketone-body utilization. Thus animals bearing both the MAC16 and MAC13 tumours show a significant (P < 0.05) elevation of brain 3-oxoacid CoA-transferase activity (1.8 + 0.2 and 1.5 + 0.1 unmol/min per mg of protein respectively) as compared with non-tumour-bearing controls (1.2 + 0.1 umol/min per mg of protein). (Fig. 2) . This suggests that in tumour-bearing animals brain metabolism is supported by an increased utilization of 3-hydroxybutyrate, as occurs in starvation, and this appears to be independent of the development of cachexia.
DISCUSSION
Glucose is an important metabolic substrate, particularly for solid tumours [20] , possibly owing to a poor vascularization, which would militate against oxidative metabolism. In a study of energy production by a rapidly growing hepatoma cell line, it was estimated that about 600% of the total ATP was derived from glycolysis and 40% from oxidative phosphorylation [21] . In the present study the glucose consumption by the colon adenocarcinomas of the MAC series has been shown to be high (0.7-1.1 ,umol/min per g) and comparable with that of the brain (0.8 ,umol/min per g). Interestingly, the rate of glucose utilization by the MAC16 tumour was lower than that by the MAC13 tumour and independent of the production of cachexia in the animal, suggesting that the high glucose consumption by the tumour is not sufficient to explain the loss of host body compartments.
The tumour-bearing state also induces profound changes in glucose utilization by host organs, and in particular by the brain, where glucose utilization is severely depressed. Previous studies [22] (8 mM) [25] . This system paralleled the study in vivo using 2DG, in that, although glucose was the predominant metabolic fuel for the brain in non-tumour-bearing animals, its importance in oxidative metabolism was decreased in the tumour-bearing situation, especially in animals bearing the cachexia-inducing MAC16 tumour, where its use was replaced by lactate and 3-hydroxybutyrate. Ketone bodies have been shown to replace glucose as the predominant fuel for brain metabolism during starvation [26] . Thus the brains of cachectic animals bearing the MAC16 tumour resemble those during starvation, although the food intake is not decreased [11, 12] . In the rat, the major factor influencing the rate of utilization of ketone bodies has been suggested to be the concentration in the blood [19] . However, although extensive mobilization of adipose tissue is observed in animals bearing the MAC16 tumour, no elevations in plasma or urinary levels of ketone bodies have been detected [11] . In addition, in the situation in vitro, the concentrations of glucose, lactate and 3-hydroxybutyrate in the incubation medium remained constant, suggesting that the enzymes which regulate ketone-body utilization in the brain of tumour-bearing animals may be altered. This hypothesis was confirmed by measurements of the levels of 3-oxoacid CoA-transferase, the rate-limiting enzyme in ketone-body utilization, which was shown to be significantly enhanced in animals bearing both the MAC16 and MAC13 tumours. In contrast, the level of acetoacetyl-CoA thiolase was not significantly different between tumour-bearing (18.3 + 4.1 ,umol/min per mg ofprotein) and non-tumour-bearing (22.0 + 6.6 ,umol/min per mg of protein) animals.
We have previously shown that 3-oxoacid CoA-transferase is also present in the MAC16 tumour, but at decreased levels compared with normal colon [27] . The activity of the enzyme in liver is low or non-detectable, and coincides with a low rate of utilization of 3-hydroxybutyrate by liver slices in vitro, whereas the rate of oxidation by tumour tissue was 3-10 times higher. For the MAC13 tumour, lactate was the most important metabolic fuel at the high concentration employed, and lactate has also been shown to be utilized by a number of rat tumours in vivo [28] . utilization by host organs, principally the brain, accompanied by utilization of ketone bodies as an alternative metabolic fuel. Utilization of ketone bodies appears to result from an increased activity of 3-oxoacid CoA-transferase without an alteration in substrate availability. This change appears not to be specific for the cachectic state, although the increased metabolic demand on the host is associated with an increased food intake in animals bearing the MAC13 tumour, whereas animals bearing the MAC16 tumour have the same food intake as non-tumourbearing controls. Thus cachexia could arise from an inability of the host to adapt to the increased metabolic requirements of the tumour-bearing state.
